

March 2, 2016



# Adaptimmune to Present at Cowen and Company's 36th Annual Health Care Conference

PHILADELPHIA and OXFORD, United Kingdom, March 02, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that James Noble, Chief Executive Officer of Adaptimmune, will present at Cowen and Company's 36<sup>th</sup> Annual Health Care Conference on Monday, March 7<sup>th</sup> at 4:40 PM (9:40 PM GMT). The conference is being held at the Boston Marriott Copley Place, in Boston, MA.

Adaptimmune's presentation will be webcast live for investors through the investor section of [www.adaptimmune.com](http://www.adaptimmune.com) and available for a period of 30 days following the conference.

## About Adaptimmune

Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor (TCR) platform. Established in 2008, the company aims to utilize the body's own machinery - the T-cell - to target and destroy cancer cells by using engineered, increased affinity TCRs as a means of strengthening natural patient T-cell responses. Adaptimmune's lead program is an affinity enhanced T-cell therapy targeting the NY-ESO cancer antigen. Its NY-ESO TCR affinity enhanced T-cell therapy has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types, including synovial sarcoma and multiple myeloma. Adaptimmune has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO TCR program. In addition, Adaptimmune has a number of proprietary programs. The company has identified over 30 intracellular target peptides preferentially expressed in cancer cells and is currently progressing 12 through unpartnered research programs. Adaptimmune has over 200 employees and is located in Oxfordshire, U.K. and Philadelphia, USA. For more information: <http://www.adaptimmune.com>.

## Adaptimmune Contacts

Will Roberts  
Vice President, Investor Relations  
T: (215) 825-9306  
E: [will.roberts@adaptimmune.com](mailto:will.roberts@adaptimmune.com)

Margaret Henry  
Head of PR  
T: +44 (0)1235 430036  
Mob: +44 (0)7710 304249  
E: [margaret.henry@adaptimmune.com](mailto:margaret.henry@adaptimmune.com)



Source: Adaptimmune Therapeutics plc